-
CRWD Stock Could Soar 16%, Says Wedbush's Dan Ives: 'Coming In Very Strong With Healthy Momentum'
Thursday, July 3, 2025 - 7:26am | 840Wedbush Securities analyst Dan Ives has raised the price target for CrowdStrike Holdings Inc. (NASDAQ:CRWD) to $575, signaling robust optimism about the cybersecurity leader's trajectory. What Happened: The announcement, shared via an X post, highlights a projected 16% upside for the stock over the...
-
Rivian Stock Above $15, But UBS Sees Fair Value At $13 Amid Affordability Concerns
Tuesday, May 27, 2025 - 9:09am | 456Investment bank UBS Group AG has maintained a Neutral rating for Rivian Automotive Inc. (NASDAQ:RIVN) stock and has upgraded its price target to $13 from $12. The stock closed last session at $15.63 apiece What Happened: Analysts from the Swiss investment bank see a positive long-term outlook for...
-
Newmont Soars With A New $60 Price Target, Leads S&P 500 Higher
Friday, April 11, 2025 - 3:42pm | 447Newmont Corporation (NYSE:NEM) received an upgrade from UBS from Neutral to Buy, setting a 12-month price target of $60 per share. The bank cited a significantly more favorable gold market outlook and the company's improved capital return potential following strategic divestments. UBS sees gold...
-
Bank of America Calls New Gold A Buy, Lifts Price Target By 50%
Wednesday, March 26, 2025 - 1:43pm | 449Bank of America upgraded Canadian intermediate gold miner New Gold (AMEX:NGD) from Underperform to Buy. The double upgrade saw the bank’s analysts raise the price target by 50%, to $3.90, citing strong production growth, lower costs, and increasing free cash flow. Analysts who see a...
-
CyberArk Stock Poised To Surge Nearly 22%, Says BofA: 'Metrics Show Continued Execution On All Fronts'
Wednesday, February 19, 2025 - 8:50am | 566Bank of America Securities analyst, Madeline Brooks, has increased the price target for CyberArk Software (NASDAQ:CYBR) by $145 to $500, indicating a potential surge in the company’s shares. What Happened: Brooks maintained a Buy rating on CyberArk’s stock, attributing the...
-
Freeport-McMoRan Scores A Solid Q3, Analysts Say: 'Benefit From High Copper And Gold Prices'
Wednesday, October 23, 2024 - 4:33pm | 512Freeport-McMoRan (NYSE:FCX) closed Wednesday’s trading session 1.26% lower at $47.92 as the market further digested its third-quarter earnings results. The leading copper miner reported slightly lower earnings per share, coming at $0.36 instead of the expected $0.37, while soundly beating the...
-
MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds
Friday, March 8, 2024 - 2:01pm | 712Shortly following the news on FDA's "breakthrough therapy" designation and the 12-week clinical durability data on its LSD therapy for generalized anxiety, psychedelics biotech MindMed (NASDAQ:MNMD) announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per...
-
Microsoft's 'iPhone Moment': Shares Dip But Analysts Remain Positive After Ignite Event
Friday, November 17, 2023 - 1:50pm | 468Microsoft’s (NASDAQ:MSFT) shares were lower in morning trade on Friday. Tech stocks were sold off on all the major indices. This week, the company held its annual Ignite conference. It unveiled a range of new and updated artificial intelligence (AI) and cloud offerings. One analyst equated...
-
How Analyst Ratings Can Help You Pick The Right Stocks
Wednesday, August 23, 2017 - 11:22am | 694Traders are known to have strong convictions on how any given stock is going to perform. Most traders are also seasoned enough to take these passing opinions on future price action with a grain of salt. Nonetheless, there are those whose informed opinion might just be worth listening to....
-
Looking Ahead Of Wall Street: MEI Pharma, Sarepta, Novavax & More
Sunday, September 13, 2015 - 1:12pm | 1038Now that Wall Street is in the second half of the year, analysts are anticipating updates and announcements about pipeline drugs from biopharmaceutical companies, including MEI Pharma Inc (NASDAQ:MEIP), Sarepta Therapeutics (NASDAQ:SRPT), Novavax, Inc. (NASDAQ:NVAX), and XOMA Corp (NASDAQ:XOMA)....
-
3 JPMorgan Bull Calls Hitting The Market
Thursday, April 2, 2015 - 2:25pm | 362Two pharmaceutical companies received new coverage at J.P Morgan Thursday with favorable ratings. Both Endo International plc (NASDAQ: ENDP) and Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were launched with Overweight ratings by the investment bank. Separately, J.P Morgan upgraded the...
-
Analysts See In-Line Q1 For Nike Inc; Currency Impact Questioned
Tuesday, September 23, 2014 - 5:55pm | 380Nike Inc (NYSE: NKE) posts fiscal first-quarter earnings Thursday while analysts eyeball a mixed bag in commodity costs and currency impacts. Cotton prices are near record lows while rubber prices continue to decline, Macquarie's Laurent Vasilescu said in a note. Leather prices,...
-
Benzinga's Top Upgrades
Friday, May 23, 2014 - 7:34am | 154Analysts at Janney Capital upgraded Portfolio Recovery Associates, Inc. (NASDAQ: PRAA) from “neutral” to “buy.” The target price for Portfolio Recovery Associates is set to $60. Portfolio Recovery Associates' shares closed at $53.03 yesterday. JP Morgan upgraded RTI International Metals, Inc. (...
-
Top IT and BPO Services Stocks Recommended by JP Morgan
Wednesday, January 25, 2012 - 3:35pm | 2046By Insider Monkey Staff, January 24 J.P. Morgan published a report entitled “IT and BPO Services” on January 12, 2012. The report isn’t publicly available but we will share its main points. In the report, Tien-tsin Huang, Puneet Jain, and Dick Wei share their opinion of the IT and BPO...
-
The Ratings Agencies, Part I: Experts or Charlatans?
Sunday, August 21, 2011 - 11:58am | 970I hate hypocrites. It's no secret. I've stated it on countless occasions in previous commentaries. Supposedly, the Western legal system (the literal “foundation” of our democracies) “hates hypocrites” as well. To be specific, supposedly our legal systems don't allow a group of people to call...